Effective Xiaflex administration for Peyronie disease involves back-to-back injections and achieving an erection with the first injection of each series. Optimizing dosage, dilution, and incorporating ...

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS. In this interview, ...

Five-fraction SBRT showed noninferiority to conventional radiotherapy in localized prostate cancer, with 95.8% of patients free from failure at five years. SBRT offers a shorter treatment duration, ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

Active surveillance is effective for low-risk prostate cancer, with low metastasis and mortality rates over 10 years. The study underscores the need for improved risk stratification to minimize ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

Route of administration impacts patient compliance and convenience, influencing the choice of PD-1/PD-L1 agents. Duration of therapy affects patients' quality of life and is a key consideration in ...

Ga-PSMA and F-Fluciclovine PET/CT significantly increased radiotherapy target volumes post-prostatectomy, with F-Fluciclovine leading to more prostate bed boosts. F-Fluciclovine showed higher prostate ...

The NRG-GU011 trial evaluates relugolix plus SBRT versus SBRT alone in men with PSA recurrence and PSMA-PET-detected metastases. The study addresses whether targeted radiation can delay hormone ...

UGN-102's NDA acceptance marks a potential first FDA-approved treatment for LG-IR-NMIBC, with a PDUFA date of June 13, 2025. The phase 3 ENVISION trial demonstrated a 79.6% complete response rate at 3 ...

"Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis," says Cedric Pobel, MD.